|13 April 2017||Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals|
|Purchase price of US$6.72 per share, or approximately US$85 million
Acquisition to strengthen Zoetis’ pipeline in companion animal
therapeutics for chronic pain, a global area estimated at US$400
PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Apr. 13, 2017--
Inc. (NYSE:ZTS) and Nexvet
Biopharma plc (Nasdaq:NVET) today announced an agreement in which
|22 February 2017||Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference|
|DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET.
Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, consisting of ranevetmab and frunevetmab; the significant progress made at the Company’s manufac... |
|10 February 2017||Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017|
|DUBLIN, Ireland, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2016.
Initiated pivotal field efficacy and safety studies of frunevetmab, the Company’s anti-nerve growth factor monoclonal antibody (anti-NGF mAb) in development for the control of pain associated with osteoarthritis in cats
Entered into a research collaboration with Genentech
|12 December 2016||Nexvet Announces Initiation of Pivotal Efficacy Study of Frunevetmab in Cats |
|DUBLIN, Ireland, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced it has initiated a pivotal field efficacy and safety study of frunevetmab, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy which is being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats. Nexvet expects to report data from both this study and a currently running pivotal target animal safety study of fruneve... |